Compare Oatly Group AB - ADR (OTLY) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs ResMed Inc. — how do they compare? Oatly Group AB - ADR trades at $12.57 (market cap $432.09M), while ResMed Inc. trades at $219.5 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 73.8× Oatly Group AB - ADR's market cap, and ResMed Inc. pays a 1.19% dividend while Oatly Group AB - ADR pays none. Which is the better fit depends on your goals.
| OTLY | RMD | |
|---|---|---|
Market Cap | $432.09M | $31.89B |
Sector | Consumer Staples | Health |
52-Week High | $18.09 | $283.28 |
52-Week Low | $8.03 | $182.82 |
Enterprise Value | $936.50M | $31.24B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OTLY trades at $13.52, down 3.98% today, with a bullish technical signal supported by a recent golden cross and oversold RSI. Revenue growth improved to $862M in 2025, but net losses persist at -$153M, with negative cash flows. Analysts are mixed with 44% buy ratings, while the company raised its 2026 revenue outlook after Q2 results.
The outlook hinges on Oatly's path to profitability; accelerating revenue and margin improvements offer upside, but high debt and sustained losses pose significant risks. Investors should weigh operational progress against financial instability in a competitive plant-based market.
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
